Why is Cohance Life falling/rising?

As of 18-Nov, Cohance Lifesciences Ltd is experiencing a decline in its stock price, currently at Rs. 595.65, which reflects a decrease of Rs. 15.5 or 2.54%. The stock has hit a new 52-week low of Rs. 593.5 today and has been on a consecutive fall for the last 14 days, resulting in a significant drop of 30.29% over this period. Additionally, the stock has underperformed its sector by 1.91% today and is trading below all major moving averages. The company has also seen a decline in investor participation, with delivery volume dropping by 27.66% against the 5-day average. Despite having a high return on equity (ROE) of 21.07% and a low debt-to-equity ratio, the stock's long-term growth prospects appear poor, with operating profit growth at only 4.15% over the last five years. The recent negative financial results, including a 42.4% drop in profit before tax and a 27.4% decline in profit after tax compared to previous quarters, further exacerbate the stock's downward trend. In the broader market context, the stock has significantly underperformed relative to the Sensex, with a 1-week return of -13.84% compared to the benchmark's positive return of 0.96%. Over the past year, Cohance Lifesciences Ltd has generated a return of -53.64%, while the Sensex has increased by 9.48%. This stark contrast highlights the challenges the company faces in attracting investor confidence, especially given that 100% of promoter shares are pledged, which adds downward pressure in a falling market. The combination of poor short-term performance, disappointing financial results, and high valuation compared to peers contributes to the stock's current decline.